Modulation of peanut-induced allergic immune responses by oral lactic acid bacteria-based vaccines in mice
- 562 Downloads
Peanut allergy (PNA) has becoming a non-negligible health concern worldwide. Thus far, allergen-specific immunotherapy aimed at inducing mucosal tolerance has widely been regarded as a major management strategy for PNA. The safety profiles and the intrinsic probiotic properties of lactic acid bacteria (LAB) render them attractive delivery vehicles for mucosal vaccines. In the present study, we exploited genetically modified Lactococcus lactis to produce peanut allergen Ara h 2 via different protein-targeting systems and their immunomodulatory potency for allergic immune responses in mice were investigated. By comparison with the strain expressing the cytoplasmic form of Ara h 2 (LL1), the strains expressing the secreted and anchored forms of Ara h 2 (LL2 and LL3) were more potent in redirecting a Th2-polarized to a non-allergic Th1 immune responses. Induction of SIgA and regulatory T cells were also observed at the local levels by orally administration of recombinant L. lactis. Our results indicate that allergen-producing L. lactis strains modulated allergic immune responses and may be developed as promising mucosal vaccines for managing allergic diseases.
KeywordsPeanut allergy Immunomodulation Oral tolerance Lactococcus lactis
This work was supported by the National Natural Science Foundation of China (No. 31200691), the National Science Fund for Distinguished Young Scholars (No. 31125021), the National Science & Technology Pillar Program in the Twelfth Five-year Plan Period (No. 2013BAD18B01, 2013BAD18B02, 2012BAD28B07, 2012BAD28B08), the 111 project B07029, IRT1249, and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.
Conflict of interest
The authors declare that they have no conflict of interest.
- Al-Muhsen S, Clarke AE, Kagan RS (2003) Peanut allergy: an overview. Can Med Assoc J 168(10):1279–1285Google Scholar
- Burks AW, Williams LW, Connaughton C, Cockrell G, O'Brien TJ, Helm RM (1992) Identification and characterization of a second major peanut allergen, Ara h II, with use of the sera of patients with atopic dermatitis and positive peanut challenge. J Allergy Clin Immunol 90(6, Part 1):962–969PubMedCrossRefGoogle Scholar
- Gasson MJ (1983) Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 154(1):1–9Google Scholar
- Holo H, Nes IF (1989) High-frequency transformation, by electroporation, of Lactococcus lactis subsp. cremoris grown with glycine in osmotically stabilized media. J Appl Microbiol 55(12):3119–3123Google Scholar
- Jing H, Yong L, Haiyan L, Yanjun M, Yun X, Yu Z, Taiming L, Rongyue C, Liang J, Jie W, Li Z, Jingjing L (2011) Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice. Vaccine 29(24):4102–4109PubMedCrossRefGoogle Scholar
- Koppelman SJ, Wensing M, Ertmann M, Knulst AC, Knol EF (2004) Relevance of Ara h1, Ara h2 and Ara h3 in peanut-allergic patients, as determined by immunoglobulin E Western blotting, basophil–histamine release and intracutaneous testing: Ara h2 is the most important peanut allergen. Clin Exp Allergy 34(4):583–590PubMedCrossRefGoogle Scholar
- Kuipers OP, Ruyter PG de, Kleerebezem M, Vos WM de (1998) Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 64(1):15–21Google Scholar
- Le Loir Y, Azevedo V, Oliveira S, Freitas D, Miyoshi A, Bermúdez-Humarán L, Nouaille S, Ribeiro L, Leclercq S, Gabriel J, Guimaraes V, Oliveira M, Charlier C, Gautier M, Langella P (2005) Protein secretion in Lactococcus lactis : an efficient way to increase the overall heterologous protein production. Microb Cell Fact 4(1):1–13CrossRefGoogle Scholar
- Li X-M, Srivastava K, Grishin A, Huang C-K, Schofield B, Burks W, Sampson HA (2003a) Persistent protective effect of heat-killed Escherichia coli producing “engineered”, recombinant peanut proteins in a murine model of peanut allergy. J Allergy Clin Immunol 112(1):159–167Google Scholar
- Mierau I, Kleerebezem M (2005) Ten years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68(6):705–717Google Scholar
- Mondoulet L, Dioszeghy V, Larcher T, Ligouis M, Dhelft V, Puteaux E, Cherel Y, Letourneur F, Dupont C, Benhamou P-H (2012) Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS ONE 7(2):e31967PubMedCentralPubMedCrossRefGoogle Scholar
- Schwarzer M, Repa A, Daniel C, Schabussova I, Hrncir T, Pot B, Stepankova R, Hudcovic T, Pollak A, Tlaskalova-Hogenova H, Wiedermann U, Kozakova H (2011) Neonatal colonization of mice with Lactobacillus plantarum producing the aeroallergen Bet v 1 biases towards Th1 and T-regulatory responses upon systemic sensitization. Allergy 66(3):368–375PubMedCrossRefGoogle Scholar
- Taylor SL, Hefle SL, Bindslev-Jensen C, Bock SA, Burks AW Jr, Christie L, Hill DJ, Host A, Hourihane JOB, Lack G, Metcalfe DD, Moneret-Vautrin DA, Vadas PA, Rance F, Skrypec DJ, Trautman TA, Yman IM, Zeiger RS (2002) Factors affecting the determination of threshold doses for allergenic foods: how much is too much? J Allergy Clin Immunol 109(1):24–30PubMedCrossRefGoogle Scholar